Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Molecular Imaging and Biology
Published in: Molecular Imaging and Biology 5/2009

01-09-2009 | Research Article

Comparison of [18F]-Tracers in Various Experimental Tumor Models by PET Imaging and Identification of an Early Response Biomarker for the Novel Microtubule Stabilizer Patupilone

Authors: T. Ebenhan, M. Honer, S.M. Ametamey, P.A. Schubiger, M. Becquet, S. Ferretti, C. Cannet, M. Rausch, P.M.J. McSheehy

Published in: Molecular Imaging and Biology | Issue 5/2009

Login to get access

Abstract

Purpose

The suitability of [18F]FDG, [18F]FLT, [18F]FET, and [18F]FCH as non-invasive positron emission tomography (PET) biomarkers for monitoring response to chemotherapy was analyzed in various experimental tumor models.

Procedures

Tracer uptake into three syngeneic rodent tumor models and ten human xenograft models was evaluated using semiquantitative analysis of small-animal PET data. Murine RIF-1 fibrosarcomas and [18F]FLT were selected to monitor the effects of the novel cytotoxic patupilone.

Results

Except [18F]FCH, all tracers provided good tumor visualization. Highest [18F]FDG uptake was identified in syngeneic tumors. Xenograft models, however, showed low [18F]FDG SUVs and were better visualized by [18F]FLT. Monitoring the effects of patupilone on [18F]FLT uptake in RIF-1 tumors revealed a significant decrease of tracer uptake after 24 h, which strongly negatively correlated with apoptosis.

Conclusion

[18F]FLT PET of experimental tumors is a viable complement to [18F]FDG for preclinical drug development. [18F]FLT may be an excellent biomarker for patupilone-induced apoptosis.
Literature
1.
Phelps ME (2000) Positron emission tomography provides molecular imaging of biological processes. Proc Natl Acad Sci U S A 97:9226–9233PubMedCrossRef
2.
Di Chiro G, De La Paz RL, Brooks RA et al (1982) Glucose utilization of cerebral gliomas measured by [18F]fluorodeoxyglucose and positron emission tomography. Neurology 32:1323–1329PubMed
3.
Hicks RJ, Kalff V, MacManus MP et al (2001) 18F-FDG PET provides high-impact and powerful prognostic stratification in staging newly diagnosed non-small cell lung cancer. J Nucl Med 42:1596–1604PubMed
4.
Weber WA (2005) Use of PET monitoring cancer therapy and for predicting outcome. J Nucl Med 46:983–995PubMed
5.
Lammertsma AA, Hoekstra CJ, Giaccone G et al (2006) How should we analyse FDG PET studies for monitoring tumour response. Eur J Nucl Med Mol Imaging 33:16–21PubMedCrossRef
6.
Kenny LM, Aboagye EO, Price RM (2004) Positron emission tomography imaging of cell proliferation in oncology. Clin Onc 16:176–185CrossRef
7.
Spaeth N, Wyss MT, Weber B et al (2004) Uptake of 18F-fluorocholine, 18F-fluoroethyl-l-tyrosine, and 18F-FDG in acute cerebral radiation injury in the rat: implications for separation of radiation necrosis from tumour recurrence. J Nucl Med 45:1931–1938PubMed
8.
Katz-Brull R, Degani H (1996) Kinetics of choline transport and phosphorylation in human breast cancer cells: NMR application of the zero trans method. Anticancer Res 16:1375–1380PubMed
9.
Belt JA, Marina NM, Phelps DA et al (1993) Nucleoside transport in normal and neoplastic cells. Adv. Enzyme Regul 33:235–252PubMedCrossRef
10.
11.
Shields AF, Grierson JR, Dohmen BM et al (1998) Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med 4:1334–1336PubMedCrossRef
12.
Grierson JR, Shields AF (2000) Radiosynthesis of 3′-deoxy-3′-[18F]fluorothymidine: [18F]FLT for imaging of cellular proliferation in vivo. Nucl Med Biol 27:143–156PubMedCrossRef
13.
Rasey JS, Grierson JR, Wiens LW et al (2002) Validation of FLT uptake as a measure of thymidine kinase-1 activity in A549 carcinoma cells. J Nucl Med 438:1210–1217
14.
Buck AK, Halter G, Schirrmeister H et al (2003) Imaging proliferation in lung tumours with PET: 18F-FLT versus 18F-FDG. J Nucl Med 44:1432–1434
15.
Mier W, Haberkorn U, Eisenhut M (2002) [18F]FLT; portrait of a proliferation marker. Eur J Nucl Med 29:165–169CrossRef
16.
Shields AF (2006) Positron emission tomography measurement of tumour metabolism and growth: its expanding role in oncology. Mol Imaging Biol 8:141–150PubMedCrossRef
17.
Kenny LM, Aboagye EO, Price PM (2004) Positron emission tomography imaging of cell proliferation in oncology. Clin Oncol 16:176–185CrossRef
18.
Heiss P, Mayer S, Herz M et al (1999) Investigation of transport mechanism and uptake kinetics of O-(2-[18F]fluoroethyl)-l-tyrosine in vitro and in vivo. J Nucl Med 40:1367–1373PubMed
19.
Wester HJ, Herz M, Weber W et al (1999) Synthesis and radiopharmacology of O-(2-[18F]fluoroethyl)-l-tyrosine for tumour imaging. J Nucl Med 40:205–212PubMed
20.
Pauleit D, Stoffels G, Schaden W et al (2005) PET with O-(2-18F-fluoroethyl)-l-tyrosine in peripheral tumours: first clinical results. J Nucl Med 46:411–416PubMed
21.
Langen KJ, Hamacher K, Weckesser M et al (2006) O-(2-[18F]fluoroethyl)-l-tyrosine: uptake mechanisms and clinical applications. Nucl Med Biol 33:287–294PubMedCrossRef
22.
Wyss MT, Spaeth N, Biollaz G et al (2007) Uptake of 18F-fluorocholine, 18F-FET, and 18F-FDG in C6 gliomas and correlation with 131I-SIP(L19), a marker of angiogenesis. J Nucl Med 48:608–614PubMedCrossRef
23.
Wang HE, Wu SY, Chang CW et al (2005) Evaluation of F-18-labeled amino acid derivatives and [18F]FDG as PET probes in a brain tumour-bearing animal model. Nucl Med Biol 32:367–375PubMedCrossRef
24.
Rau FC, Weber WA, Wester HJ et al (2002) O-(2-[18F]fluoroethyl)-l-tyrosine (FET): a tracer for differentiation of tumour from inflammation in murine lymph nodes. J Nucl Med 29:1039–1046CrossRef
25.
DeGrado TR, Baldwin SW, Wang S et al (2001) Synthesis and evaluation of 18F-labeled choline analogs as oncologic PET tracers. J Nucl Med 42:1805–1814PubMed
26.
Price DT, Coleman RE, Liao RP et al (2002) Comparison of [18F]fluorocholine and [18F]fluorodeoxyglucose for positron emission tomography of androgen dependent and androgen independent prostate cancer. J Urol 168:273–280PubMedCrossRef
27.
Hara T, Kosaka N, Kishi H (1998) PET imaging of prostate cancer using carbon-11-choline. J Nucl Med 39:990–995PubMed
28.
Shinoura N, Nishijima M, Hara T et al (1997) Brain tumours: detection with C-11 choline PET. Radiology 202:497–503PubMed
29.
Hara T, Inagaki K, Kosaka N et al (2000) Sensitive detection of mediastinal lymph node metastasis of lung cancer with 11C-choline PET. J Nucl Med 41:1507–1513PubMed
30.
Hara T, Bansal A, DeGrado TR (2006) Choline transporter as a novel target for molecular imaging of cancer. Mol Imaging 5:498–509PubMed
31.
McSheehy PMJ Allegrini PR Ametamey SM et al (2005) The anticancer agent RAD001 rapidly inhibits 18F-FDG uptake by sensitive but not resistant tumours. 52nd Meeting Society Nuclear Medicine, abstract 1238
32.
Altmann K-H (2003) Epothilone B and its analogs—a new family of anticancer agents. Mini Rev Med Chem 3:149–158PubMedCrossRef
33.
Goodin S, Kane MP, Rubin EH (2004) Epothilones: mechanism of action and biologic activity. J Clin Oncol 22:2015–2025PubMedCrossRef
34.
Ferretti S, Allegrini PR, O’Reilly T et al (2005) Patupilone induced vascular disruption in orthotopic rodent tumour models detected by magnetic resonance imaging and interstitial fluid pressure. Clin Cancer Res 11:7773–7784PubMedCrossRef
35.
Leyton J, Latigo JR, Perumal M et al (2005) Early detection of tumour response to chemotherapy by 3′-deoxy-3′[18F]fluorothymidine positron emission tomography: the effect of cisplatin on a fibrosarcoma tumour model in vivo. Cancer Res 65:4202–4010PubMedCrossRef
36.
Kim WD, Ahn D, Oh Y et al (2006) New class of SN2 reactions catalyzed by protic solvents: facile fluorination for isotopic labeling of diagnostic molecules. J Am Chem Soc 128:16394–16397PubMedCrossRef
37.
Rudin M, McSheehy PMJ, Allegrini PR et al (2005) PTK787/ZK222584, a tyrosine kinase inhibitor of vascularendothelial growth factor receptor, reduces uptake of the contrast agent GdDOTA by murine orthotopic B16/BL6 melanoma tumours and inhibits their growth in vivo. NMR Biomed 18:308–332PubMedCrossRef
38.
Missimer J, Madi Z, Honer M et al (2004) Performance evaluation of the 16-module quad-HIDAC small animal PET camera. Phys Med Biol 49:2069–2081PubMedCrossRef
39.
Jeavons AP, Chandler RA, Dettmar CAR (1999) A 3D HIDAC-PET camera with submillimetre resolution for imaging small animals. IEEE Trans Nucl Sci 46:468–473CrossRef
40.
Reader AJ, Erlandsson K, Flower MA et al (1998) Fast accurate iterative reconstruction for low-statistics positron volume imaging. Phys Med Biol 43:835–846PubMedCrossRef
41.
Mikolajczyk K, Szabatin M, Rudnicki P et al (1998) A JAVA environment for medical image data analysis: initial application for brain PET quantification. Med Inform (Lond) 23:207–214CrossRef
42.
O’Reilly T, Wartmann M, Brueggen J et al (2009) Pharmacokinetic profile of the novel microtubule stabilizer patupilone in tumour-bearing rodents and comparison of anti-cancer activity with other MTS in multi-drug resistant human colon tumour cells in vitro and in vivo. Cancer Chemother. Pharmacol 62(6):1045–1054
43.
McSheehy PMJ, Robinson S, Ojugo A et al (1998) Carbogen breathing increases 5-fluorouracil uptake and cytotoxicity in hypoxic RIF-1 tumours: a magnetic resonance study in vivo. Cancer Res 58:1185–1194PubMed
44.
Lee L, Sharma S, Morgan B et al (2006) Biomarkers for assessment of pharmacologic activity for a vascular endothelial growth factor (VEGF) receptor inhibitor, PTK787/ZK 222584 (PTK/ZK): translation of biological activity in a mouse melanoma metastases model to phase I studies in patients with advanced colorectal cancer with liver metastases. Cancer Chemother Pharmacol 7:761–771CrossRef
45.
Robinson S, Rijken P, Howe F et al (2003) Assessment of tumour vascular development and function by susceptibility MRI methods and immunohistochemistry. J Magn Res 17:445–454CrossRef
46.
Cooper RA, Carrington BM, Loncaster JA et al (2000) Tumour oxygenation levels correlate with dynamic contrast-enhanced magnetic resonance imaging parameters in carcinoma of the cervix. Radiother Oncol 57:53–59PubMedCrossRef
47.
Rajendran JG, Mankoff DA, O’Sullivan F et al (2004) Hypoxia and glucose metabolism in malignant tumors: evaluation by [18F]fluoromisonidazole and [18F]fluorodeoxyglucose positron emission tomography imaging. Clin Cancer Res 10:2245–2252PubMedCrossRef
48.
Fueger BJ, Czernin J, Hildebrandt I et al (2006) Impact of animal handling on the results of 18F-FDG PET studies in mice. J Nucl Med 47:999–1006PubMed
49.
Lee K-H, Ko B-H, Paik J-Y et al (2005) Effects of anesthetic agents and fasting duration on 18F-FDG biodistribution and insulin levels in tumor-bearing mice. J Nucl Med 46:1531–1536PubMed
50.
Apisarnthanarax S, Alauddin MM, Mourtada F et al (2006) Early detection of chemoradioresponse in esophageal carcinoma by 3′-Deoxy-3′-3H-fluorothymidine using preclinical tumour models. Clin Cancer Res 12:4590–4597PubMedCrossRef
51.
Landberg G, Tan EM, Roos G (1990) Flow cytometric multiparameter analysis of proliferating cell nuclear antigen/cyclin and Ki-67 antigen: a new view of the cell cycle. Exp Cell Res 187(1):111–118PubMedCrossRef
52.
Quiñones-Hinojosa A, Sanai N, Smith JS (2005) Techniques to assess the proliferative potential of brain tumours. J Neurooncol 74:19–30PubMedCrossRef
53.
Eriksson S, Kierdaszuk B, Munch-Petersen B et al (1991) Comparison of the substrate specificities of human thymidine kinase 1 and 2 and deoxycytidine kinase toward antiviral and cytostatic nucleoside analogs. Biochem Biophys Res Commun 176:586–592PubMedCrossRef
Metadata
Title
Comparison of [18F]-Tracers in Various Experimental Tumor Models by PET Imaging and Identification of an Early Response Biomarker for the Novel Microtubule Stabilizer Patupilone
Authors
T. Ebenhan
M. Honer
S.M. Ametamey
P.A. Schubiger
M. Becquet
S. Ferretti
C. Cannet
M. Rausch
P.M.J. McSheehy
Publication date
01-09-2009
Publisher
Springer-Verlag
Published in
Molecular Imaging and Biology / Issue 5/2009
Print ISSN: 1536-1632
Electronic ISSN: 1860-2002
DOI
https://doi.org/10.1007/s11307-009-0216-1

Other articles of this Issue 5/2009

Molecular Imaging and Biology 5/2009 Go to the issue

Research Article

Evaluation of Tracer Kinetic Models for Analysis of [18F]FDDNP Studies

Research Article

Effective Inhibition of Xenografts of Hepatocellular Carcinoma (HepG2) by Rapamycin and Bevacizumab in an Intrahepatic Model

Editorial

Consensus Science and the Peer Review

Research Article

A Randomised Controlled Trial Assessing the Effect of Oral Diazepam on 18F-FDG Uptake in the Neck and Upper Chest Region

Research Article

Potential of Dual Time Point FDG-PET Imaging in Differentiating Malignant from Benign Pleural Disease

Rapid Communication

Correlating Metabolic Activity with Cellular Proliferation in Follicular Lymphomas